arXiv:2506. 14488v2 Announce Type: replace-cross Abstract: Structure-based drug design (SBDD) models are central to modern pharmaceutical research, enabling the rational exploration of protein-ligand interactions at atomic resolution.
By Dong Xu, Zhangfan Yang, Junchuang Cai, Sisi Yuan, Zexuan Zhu, Jianqiang Li, Junkai Ji
arXiv:2607. 20550v1 Announce Type: cross Abstract: The traditional "one drug, one target" paradigm of structure-based drug design (SBDD) frequently proves inadequate for treating multifactorial diseases such as cancer and neurodegenerative disorders, owing to compensatory signaling pathways and the emergence of drug resistance.
By Tianming Han, Zhijie Pan, Wenchi Ge, Qi Zhao
arXiv:2607. 18144v1 Announce Type: cross Abstract: Structure-based drug design (SBDD) leverages the 3D structure of protein targets, often complemented by other spatial constraints, to generate candidate binding molecules.
By Thomas MacDougall, Maksim Kuznetsov, Roman Schutski, Rim Shayakhmetov, Maxim Malkov, Vladimir Aladinskiy, Alex Aliper, Alex Zhavoronkov
arXiv:2608. 01007v1 Announce Type: new Abstract: Dual-target drug design aims to generate 3D molecules that can simultaneously interact with two target proteins, offering a promising route for discovering polypharmacological compounds against complex diseases.
By Jingyuan Zhou, Shikui Tu, Lei Xu
arXiv:2606. 23856v1 Announce Type: new Abstract: Generative molecular models for drug design are a promising direction with much active research.
By Konstantin Yatsenko, Arvind Thiagarajan
The paper proposes a new framework called ensemble-conditioned guidance that reframes molecular design as an optimisation over both the modes and properties of a molecule’s conformational ensemble. It allows 3D generative models to be conditioned simultaneously on multiple axes—such as shapes, pharmacophore profiles, or protein pockets—by adaptively combining vector fields from each condition. The authors introduce adaptive symmetry learning for composable conditions across reference frames, extend the framework to support flexible-size generation, and demonstrate its effectiveness on new benchmarks and practical drug‑discovery tasks, showing improved outcomes when conditioning on additional states compared to single‑state approaches.
By Ross Irwin, Alessandro Tibo, Jon Paul Janet, Simon Olsson